Journal
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
Volume 14, Issue 6, Pages 557-563Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ACI.0000000000000121
Keywords
allergen immunotherapy; allergen immunotherapy administration routes; novel vaccines
Categories
Funding
- Polish National Science Centre [011/01/B/NZ6/01872, 2012/04/M/NZ6/00355, 2012/04/A/NZ6/00407]
- Swiss National Science Foundation [320030-132899]
- Christine Kuhne-Center for Allergy Research and Education (CK-CARE) European 7th frame work project MeDALL: Mechanisms of the Development of Allergy [261357]
- Christine Kuhne-Center for Allergy Research and Education (CK-CARE) European 7th frame work project PREDICTA: Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases [260895]
Ask authors/readers for more resources
Purpose of reviewAllergen-specific immunotherapy is the only curative treatment for allergic diseases. In spite of the great progress in both vaccine development and the methods of allergen immunotherapy (AIT) in recent years, several key problems related to limited efficacy, side-effects, low patient adherence and the relatively high costs due to the long duration (3-5 years) remain to be solved. The current approaches aiming at optimization of AIT are reviewed, including both conceptual studies in experimental models and proof-of-concept - as well as large, multicenter clinical studies.Recent findingsThe most promising approaches to improve efficacy and safety of vaccine-based AIT include bypassing IgE binding and targeting allergen-specific T cells using hypoallergenic recombinant allergen derivatives and immunogenic peptides, the use of new adjuvants and stimulators of the innate immune response, the fusion of allergens to immune modifiers and peptide carrier proteins and new routes of vaccine administration.SummaryThe cloning of allergen proteins and genetic engineering enabled the production of vaccines that have well defined molecular, immunologic and biologic characteristics as well as modified molecular structure. These new compounds along with new immunization protocols can bring us closer to the ultimate goal of AIT, that is, complete cure of a large number of allergic patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available